EGLN2 and cancer: As shown in Table 2, the overall pooled analysis showed that EGLN2 rs10680577 polymorphism was significantly associated with cancer risk under all genetic models [(Ins/Del + Del/Del) vs. Ins/Ins:OR = 1.46, 95% CI = 1.34–1.60, PZ < .001; Del/Del vs. (Ins/Del + Ins/Ins): OR = 1.68, 95% CI = 1.07–2.63, PZ = .02; Del/Del vs. Ins/Ins: OR = 1.95, 95% CI = 1.28–2.95, PZ = .002; Ins/Del vs. Ins/Ins: OR = 1.40, 95% CI = 1.27–1.53, PZ < .001; Del vs. Ins: OR = 1.40, 95% CI = 1.30–1.51, PZ < .001] (Figure 2).